BioRestorative Therapies (FRA:9OF) Cyclically Adjusted Revenue per Share: €17.54 (As of Mar. 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
55 GF Score
Price €0.30
GF Value €1.34
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Cyclically Adjusted Revenue per Share?

BioRestorative Therapies FRA:9OF +1.33% 55 Cyclically Adjusted Revenue per Share is €17.54 as of Mar. 2026. GuruFocus rates FRA:9OF with a GF Score™ of 55/100 and a GF Value™ of €1.34 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioRestorative Therapies's adjusted revenue per share for the three months ended in Mar. 2026 was €0.001. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €17.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioRestorative Therapies's average Cyclically Adjusted Revenue Growth Rate was -73.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -38.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -22.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioRestorative Therapies was -7.80% per year. The lowest was -38.90% per year. And the median was -8.20% per year.

As of today (2026-07-12), BioRestorative Therapies's current stock price is €0.304. BioRestorative Therapies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €17.54. BioRestorative Therapies's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioRestorative Therapies was 1.11. The lowest was 0.01. And the median was 0.03.


BioRestorative Therapies  (FRA:9OF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioRestorative Therapies's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.304/17.54
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioRestorative Therapies was 1.11. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioRestorative Therapies Cyclically Adjusted Revenue per Share Related Terms


BioRestorative Therapies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies Cyclically Adjusted Revenue per Share Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 85.19 86.91 82.45 79.33 16.43

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.15 49.43 40.45 16.43 17.54

FRA:9OF vs CVKD, JSPR, APRE: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Cyclically Adjusted PS Ratio falls into.


FRA:9OF
55GF Score
BioRestorative Therapies Inc FRA:9OF
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioRestorative Therapies's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.001/330.2130*330.2130
=0.001

Current CPI (Mar. 2026) = 330.2130.

BioRestorative Therapies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 14.000 241.018 19.181
201609 4.000 241.428 5.471
201612 6.000 241.432 8.206
201703 7.000 243.801 9.481
201706 18.000 244.955 24.265
201709 13.000 246.819 17.392
201712 16.000 246.524 21.432
201803 7.500 249.554 9.924
201806 16.000 251.989 20.967
201809 11.000 252.439 14.389
201812 8.333 251.233 10.953
201903 6.500 254.202 8.444
201906 5.400 256.143 6.962
201909 5.833 256.759 7.502
201912 1.526 256.974 1.961
202003 0.060 258.115 0.077
202006 0.043 257.797 0.055
202009 0.033 260.280 0.042
202012 0.020 260.474 0.025
202103 0.019 264.877 0.024
202106 0.014 271.696 0.017
202109 0.008 274.310 0.010
202112 0.001 278.802 0.001
202203 0.004 287.504 0.005
202206 0.018 296.311 0.020
202209 0.008 296.808 0.009
202212 0.001 296.797 0.001
202303 0.008 301.836 0.009
202306 0.015 305.109 0.016
202309 0.002 307.789 0.002
202312 0.004 306.746 0.004
202403 0.005 312.332 0.005
202406 0.010 314.175 0.011
202409 0.026 315.301 0.027
202412 0.005 315.605 0.005
202503 0.003 319.799 0.003
202506 0.030 322.561 0.031
202509 0.001 324.800 0.001
202512 0.002 324.054 0.002
202603 0.001 330.213 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €17.54 mean?
BioRestorative Therapies (FRA:9OF) has a Cyclically Adjusted Revenue per Share of €17.54 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioRestorative Therapies and its competitors.
Is BioRestorative Therapies' Cyclically Adjusted Revenue per Share too high?
BioRestorative Therapies' current Cyclically Adjusted Revenue per Share is €17.54. Overall, BioRestorative Therapies has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Cyclically Adjusted Revenue per Share compare to CVKD and JSPR?
BioRestorative Therapies' Cyclically Adjusted Revenue per Share of €17.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current Cyclically Adjusted Revenue per Share is €17.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.34, compared to a current price of €0.30 — trading 77.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €17.54. BioRestorative Therapies' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Cyclically Adjusted Revenue per Share is €17.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.30 is trading 77.3% below its estimated GF Value™ of €1.34. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Cyclically Adjusted Revenue per Share: €17.54
  • GF Value™: €1.34 vs. price of €0.30 (77.3% below fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
55GF Score

Get the complete analysis for FRA:9OF

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price
€1.34
GF Value